Search | Clinical Trials Finder

Conditions: Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions: Oxybutynin Chloride IR, Mirabegron; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Urinary Bladder, Overactive, Pain, Lower Urinary Tract Symptoms
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions: Mirabegron; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 89 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 109
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more

Conditions: Lower Urinary Tract Symptoms, Nocturia
Interventions: Mirabegron; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Healthy Volunteers
Interventions: Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron; Drug · Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PreDiabetes
Interventions: Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Overactive Bladder (OAB)
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 103
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more

Conditions: Overactive Bladder
Interventions: electroacupncture, Mirabegron 50 MG [Myrbetriq]; Other · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Parkinsons Disease
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Daniel Burdick, MD; Individual
Eligibility: 30 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
Interventions: Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride; Behavioral · Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 99 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Obese, Metabolic Syndrome
Interventions: Mirabegron, Pioglitazone, Mirabegron and Pioglitazone; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Overactive Bladder Syndrome
Interventions: Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 82
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Overactive Bladder (OAB)
Interventions: Mirabegron, Tolterodine ER; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 22
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more

Conditions: Pre-diabetes, Obesity
Interventions: Mirabegron 50 MG, Tadalafil 10 MG, Placebo; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Urgency Urinary Incontinence
Interventions: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 15
States / cities: Tuscon, Arizona • Atherton, California • Culver City, California + 12 more

Conditions: Polycystic Ovary Syndrome
Interventions: Mirabegron, B Complex Plus Vitamin C Tablets; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ureteral Obstruction, Flank Pain
Interventions: Mirabegron, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Mechanisms for Activation of Beige Adipose Tissue in Humans

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Brown Fat Activation Study

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain